Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
BicycleTx Limited
TCR2 Therapeutics
Incyte Corporation
Incyte Corporation
Compugen Ltd
Purple Biotech Ltd.
Eli Lilly and Company
Fate Therapeutics
Incyte Corporation
Duke University
Five Prime Therapeutics, Inc.
AbbVie